Referencias bibliográficas

1. Bidesi NSR, Vang Andersen I, Windhorst AD, Shalgunov V, Herth MM. The role of neuroimaging in Parkinson's disease. J Neurochem. 2021 Nov;159(4):660-89. [Pubmed]
2. Strafella AP, Bohnen NI, Perlmutter JS, Eidelberg D, Pavese N, Van Eimeren T, et al.; IPMDS-Neuroimaging Study Group. Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Mov Disord. 2017 Feb;32(2):181-92. [Pubmed]
3. Moore RY, Whone AL, McGowan S, Brooks DJ. Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study. Brain Res. 2003 Aug 29;982(2):137-45. [Pubmed]
4. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct;30(12):1591-601. [Pubmed]
5. Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, et al.; Parkinson Study Group PRECEPT Investigators. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology. 2014 May 20;82(20):1791-7. [Pubmed]
6. Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):5-12. [Pubmed]
7. Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-García C, Jennings D, et al.; Parkinson's Progression Marker Initiative. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. Mov Disord. 2018 May;33(5):771-82. [Pubmed]
8. Perlmutter JS, Norris SA. Neuroimaging biomarkers for Parkinson disease: facts and fantasy. Ann Neurol. 2014 Dec;76(6):769-83. [Pubmed]
9. Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol. 2014 Dec;10(12):708-22. [Pubmed]
10. Politis M, Niccolini F. Serotonin in Parkinson's disease. Behav Brain Res. 2015 Jan 15;277:136-45. [Pubmed]
11. Stoessl AJ. Neuroimaging in Parkinson's disease: from pathology to diagnosis. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S55-9. [Pubmed]
12. Sommerauer M, Fedorova TD, Hansen AK, Knudsen K, Otto M, Jeppesen J, et al. Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study. Brain. 2018 Feb 1;141(2):496-504. [Pubmed]
13. Sawada H, Oeda T, Yamamoto K, Kitagawa N, Mizuta E, Hosokawa R, et al. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol. 2009 Feb;16(2):174-82. [Pubmed]
14. Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G, Giordano A. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012 Feb;22(1):43-55. [Pubmed]
15. Jiménez-Hoyuela García JM. Aplicaciones neurológicas de la gammagrafía de inervación miocárdica con (123)-I-MIBG [Neurological applications of the 123 I-MIBG myocardial innervation scintigraphy]. Rev Esp Med Nucl. 2011 May-Jun;30(3):197-204. Spanish. [Pubmed]
16. Knudsen K, Fedorova TD, Hansen AK, Sommerauer M, Otto M, Svendsen KB, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 2018 Jul;17(7):618-28. [Pubmed]
17. Meles SK, Oertel WH, Leenders KL. Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease. Mol Med. 2021 Sep 16;27(1):111. [Pubmed]
18. Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010 Feb;9(2):149-58. [Pubmed]
19. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, et al. Changes in network activity with the progression of Parkinson's disease. Brain. 2007 Jul;130(Pt 7):1834-46. [Pubmed]
20. Mattis PJ, Niethammer M, Sako W, Tang CC, Nazem A, Gordon ML, et al. Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases. Neurology. 2016 Nov 1;87(18):1925-33. [Pubmed]
21. Meles SK, Teune LK, de Jong BM, Dierckx RA, Leenders KL. Metabolic Imaging in Parkinson Disease. J Nucl Med. 2017 Jan;58(1):23-28. [Pubmed]
22. Varnäs K, Cselényi Z, Jucaite A, Halldin C, Svenningsson P, Farde L, Varrone A. PET imaging of [11C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):367-75. [Pubmed]
23. Mahlknecht P, Hotter A, Hussl A, Esterhammer R, Schocke M, Seppi K. Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. Neurodegener Dis. 2010;7(5):300-18. [Pubmed]
24. Ofori E, Pasternak O, Planetta PJ, Burciu R, Snyder A, Febo M, et al. Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study. Neurobiol Aging. 2015 Feb;36(2):1097-104. [Pubmed]
25. Mitchell T, Lehéricy S, Chiu SY, Strafella AP, Stoessl AJ, Vaillancourt DE. Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review. JAMA Neurol. 2021 Oct 1;78(10):1262-72. [Pubmed]
26. Matsuura K, Maeda M, Tabei KI, Umino M, Kajikawa H, Satoh M, et al. A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson's disease. Neurosci Lett. 2016 Oct 28;633:112-7. [Pubmed]
27. Guan X, Xu X, Zhang M. Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease. Neurosci Bull. 2017 Oct;33(5):561-7. [Pubmed]
28. Arribarat G, Péran P. Quantitative MRI markers in Parkinson's disease and parkinsonian syndromes. Curr Opin Neurol. 2020 Apr;33(2):222-9. [Pubmed]
29. Behnke S, Runkel A, Kassar HA, Ortmann M, Guidez D, Dillmann U, Fassbender K, Spiegel J. Long-term course of substantia nigra hyperechogenicity in Parkinson's disease. Mov Disord. 2013 Apr;28(4):455-9. [Pubmed]
30. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):16-34. Erratum in: Eur J Neurol. 2013 Feb;20(2):406. [Pubmed]
31. Berg D, Seppi K, Liepelt I, Schweitzer K, Wollenweber F, Wolf B, et al. Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Mov Disord. 2010 Jul 30;25(10):1464-9. [Pubmed]
32. Brockmann K, Gröger A, Di Santo A, Liepelt I, Schulte C, Klose U, Maetzler W, Hauser AK, Hilker R, Gomez-Mancilla B, Berg D, Gasser T. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord. 2011 Nov;26(13):2335-42. [Pubmed]
33. Satue M, Obis J, Rodrigo MJ, Otin S, Fuertes MI, Vilades E, et al. Optical Coherence Tomography as a Biomarker for Diagnosis, Progression, and Prognosis of Neurodegenerative Diseases. J Ophthalmol. 2016;2016:8503859. [Pubmed]
34. Alzghool OM, van Dongen G, van de Giessen E, Schoonmade L, Beaino W. α-Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives. Mov Disord. 2022 May;37(5):936-48. [Pubmed]
35. Aracil-Bolaños I, Sampedro F, Marín-Lahoz J, Horta-Barba A, Martínez-Horta S, Botí M, et al. A divergent breakdown of neurocognitive networks in Parkinson's Disease mild cognitive impairment. Hum Brain Mapp. 2019 Aug 1;40(11):3233-42. [Pubmed]
36. Aracil-Bolaños I, Sampedro F, Pujol J, Soriano-Mas C, Gónzalez-de-Echávarri JM, Kulisevsky J, Pagonabarraga J. The impact of dopaminergic treatment over cognitive networks in Parkinson's disease: Stemming the tide? Hum Brain Mapp. 2021 Dec 1;42(17):5736-46. [Pubmed]